94 related articles for article (PubMed ID: 20550119)
1. Oral oxytocin antagonists.
Borthwick AD
J Med Chem; 2010 Sep; 53(18):6525-38. PubMed ID: 20550119
[No Abstract] [Full Text] [Related]
2. Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.
Williams PD; Ball RG; Clineschmidt BV; Culberson JC; Erb JM; Freidinger RM; Pawluczyk JM; Perlow DS; Pettibone DJ; Veber DF
Bioorg Med Chem; 1994 Sep; 2(9):971-85. PubMed ID: 7712132
[TBL] [Abstract][Full Text] [Related]
3. Design and optimization of potent, selective antagonists of Oxytocin.
Brown A; Brown L; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
Bioorg Med Chem Lett; 2008 Aug; 18(15):4278-81. PubMed ID: 18639455
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of non-peptide antagonists of peptide hormone receptors.
Pettibone DJ; Freidinger RM
Biochem Soc Trans; 1997 Aug; 25(3):1051-7. PubMed ID: 9388600
[No Abstract] [Full Text] [Related]
5. Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.
Brown A; Brown L; Brown TB; Calabrese A; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
Bioorg Med Chem Lett; 2008 Oct; 18(19):5242-4. PubMed ID: 18778939
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.
Kuo MS; Bock MG; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Williams PD; Woyden CJ
Bioorg Med Chem Lett; 1998 Nov; 8(21):3081-6. PubMed ID: 9873680
[TBL] [Abstract][Full Text] [Related]
7. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
[TBL] [Abstract][Full Text] [Related]
8. Nanomolar-affinity, non-peptide oxytocin receptor antagonists.
Evans BE; Lundell GF; Gilbert KF; Bock MG; Rittle KE; Carroll LA; Williams PD; Pawluczyk JM; Leighton JL; Young MB
J Med Chem; 1993 Dec; 36(25):3993-4005. PubMed ID: 8258821
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.
Barton NP; Bellenie BR; Doran AT; Emmons AJ; Heer JP; Salvagno CM
Bioorg Med Chem Lett; 2009 Jan; 19(2):528-32. PubMed ID: 19081251
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.
Cole DC; Lennox WJ; Lombardi S; Ellingboe JW; Bernotas RC; Tawa GJ; Mazandarani H; Smith DL; Zhang G; Coupet J; Schechter LE
J Med Chem; 2005 Jan; 48(2):353-6. PubMed ID: 15658848
[TBL] [Abstract][Full Text] [Related]
12. Camphor sulfonamide derivatives as novel, potent and selective CXCR3 antagonists.
Wang Y; Busch-Petersen J; Wang F; Kiesow TJ; Graybill TL; Jin J; Yang Z; Foley JJ; Hunsberger GE; Schmidt DB; Sarau HM; Capper-Spudich EA; Wu Z; Fisher LS; McQueney MS; Rivero RA; Widdowson KL
Bioorg Med Chem Lett; 2009 Jan; 19(1):114-8. PubMed ID: 19014886
[TBL] [Abstract][Full Text] [Related]
13. The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Liddle J; Allen MJ; Borthwick AD; Brooks DP; Davies DE; Edwards RM; Exall AM; Hamlett C; Irving WR; Mason AM; McCafferty GP; Nerozzi F; Peace S; Philp J; Pollard D; Pullen MA; Shabbir SS; Sollis SL; Westfall TD; Woollard PM; Wu C; Hickey DM
Bioorg Med Chem Lett; 2008 Jan; 18(1):90-4. PubMed ID: 18032036
[TBL] [Abstract][Full Text] [Related]
14. Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives.
Wyatt PG; Allen MJ; Chilcott J; Foster A; Livermore DG; Mordaunt JE; Scicinski J; Woollard PM
Bioorg Med Chem Lett; 2002 May; 12(10):1399-404. PubMed ID: 11992786
[TBL] [Abstract][Full Text] [Related]
15. Orally active, nonpeptide oxytocin antagonists.
Evans BE; Leighton JL; Rittle KE; Gilbert KF; Lundell GF; Gould NP; Hobbs DW; DiPardo RM; Veber DF; Pettibone DJ
J Med Chem; 1992 Oct; 35(21):3919-27. PubMed ID: 1331449
[TBL] [Abstract][Full Text] [Related]
16. Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.
Brown A; Brown TB; Calabrese A; Ellis D; Puhalo N; Ralph M; Watson L
Bioorg Med Chem Lett; 2010 Jan; 20(2):516-20. PubMed ID: 19963374
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-HT6 receptor ligands based on virtual HTS.
Tasler S; Kraus J; Wuzik A; Müller O; Aschenbrenner A; Cubero E; Pascual R; Quintana-Ruiz JR; Dordal A; Mercè R; Codony X
Bioorg Med Chem Lett; 2007 Nov; 17(22):6224-9. PubMed ID: 17892934
[TBL] [Abstract][Full Text] [Related]
18. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Williams PD; Clineschmidt BV; Erb JM; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Pettibone DJ; Reiss DR; Veber DF
J Med Chem; 1995 Nov; 38(23):4634-6. PubMed ID: 7473590
[No Abstract] [Full Text] [Related]
19. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
Borthwick AD; Davies DE; Exall AM; Hatley RJ; Hughes JA; Irving WR; Livermore DG; Sollis SL; Nerozzi F; Valko KL; Allen MJ; Perren M; Shabbir SS; Woollard PM; Price MA
J Med Chem; 2006 Jul; 49(14):4159-70. PubMed ID: 16821776
[TBL] [Abstract][Full Text] [Related]
20. Oxytocin-receptor binding: why divalent metals are essential.
Liu D; Seuthe AB; Ehrler OT; Zhang X; Wyttenbach T; Hsu JF; Bowers MT
J Am Chem Soc; 2005 Feb; 127(7):2024-5. PubMed ID: 15713062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
